HMGA2 and non-small cell lung carcinoma: After systemic administration of aptamer-miRNA chimera in immune-deficient mice with an A549 NSCLC-derived tumor, there was downward adjustment of the target 7g HMGA2, as well as inhibition of tumor growth [170].